aldosterone has been researched along with Cardiac Hypertrophy in 139 studies
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown." | 9.27 | A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. ( Duran, SH; Jung, S; Newhard, DK; Winter, RL, 2018) |
| "The effects of a sustained-release formulation of the calcium antagonist nicardipine on left ventricular (LV) mass, Doppler transmitral velocity profiles and plasma neurohumoral studies were analyzed in patients with mild to moderate systemic hypertension." | 9.07 | Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. ( Adler, J; Dittrich, HC; Ong, J; Reitman, M; Weber, M; Ziegler, M, 1992) |
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 7.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 7.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy." | 7.78 | Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 7.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| "The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment." | 7.68 | Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992) |
| "To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8." | 7.68 | Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990) |
| "To study the effects of a novel angiotensin I converting enzyme inhibitor (ACEI) on hypertension-induced cardiac hypertrophy, benazepril hydrochloride (CGS 14824 A, CAS 86541-74-4) at the dose of 3 and 10 mg/kg/d p." | 7.68 | Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. ( Hasegawa, Y; Inukai, T; Katahira, J; Nakao, K; Takemori, E, 1991) |
| "To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p." | 7.67 | [Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 6.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 6.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| "Thus, BST-1 may exacerbate cardiac hypertrophy by activating the Ca2+/CaN/NFATc3 pathway." | 5.91 | BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway. ( Cao, H; Fu, L; Huang, F; Li, A; Li, S; Liao, C; Wang, X; Yuan, Y; Zeng, W; Zhang, B; Zhao, L, 2023) |
| "Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0." | 5.35 | Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009) |
| "Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis." | 5.33 | Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006) |
| "However, tempol failed to suppress cardiac hypertrophy, the formation of inflammatory lesions, and upregulation of cardiac MCP-1 and osteopontin by aldosterone, while N-acetylcysteine could inhibit all of them." | 5.33 | Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. ( Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Ueda, M; Wake, R; Yoshida, K; Yoshiyama, M; Yukimura, T, 2005) |
| "1." | 5.32 | Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. ( De Smet, HR; Menadue, MF; Oliver, JR; Phillips, PA, 2003) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 5.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "High sodium intake causes cardiac hypertrophy independently of increases in blood pressure." | 5.31 | Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000) |
| "A case of primary hyperaldosteronism and cardiomegaly due to a unilateral adrenal adenoma in a newborn is presented." | 5.30 | Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. ( Armanini, D; Cecchetto, G; Fassina, A; Opocher, G; Pozzan, GB; Rigon, F; Zacchello, F, 1997) |
| "The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown." | 5.27 | A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. ( Duran, SH; Jung, S; Newhard, DK; Winter, RL, 2018) |
| "The effects of a sustained-release formulation of the calcium antagonist nicardipine on left ventricular (LV) mass, Doppler transmitral velocity profiles and plasma neurohumoral studies were analyzed in patients with mild to moderate systemic hypertension." | 5.07 | Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. ( Adler, J; Dittrich, HC; Ong, J; Reitman, M; Weber, M; Ziegler, M, 1992) |
| "In a double-blind 6 month trial, the cardiac effects of captopril and minoxidil, administered as third step treatments, were compared in 34 men with essential hypertension and diastolic blood pressure greater than 95 mm Hg who were taking 200 mg/day of metoprolol and 80 mg/day of furosemide." | 5.06 | Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. ( Chatellier, G; Corvol, P; Dufloux, MA; Julien, J; Menard, D; Menard, J; Plouin, PF; Prasquier, R, 1990) |
| " The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure." | 4.81 | Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. ( Funder, JW; Young, MJ, 2002) |
| " We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)." | 3.83 | Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy." | 3.78 | Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012) |
| " We analysed the effects of early chronic VPI (50 mg/kg/day Omapatrilat) on cardiac remodelling and neurohumoral function during the progression of rapid ventricular pacing-induced heart failure in rabbits (early left ventricular dysfunction [ELVD]: 10 days at 330 bpm, CHF: further 10 days at 360 bpm)." | 3.78 | Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. ( Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C, 2012) |
| "To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy." | 3.78 | In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012) |
| "We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination." | 3.74 | Relations of biomarkers representing distinct biological pathways to left ventricular geometry. ( Aragam, J; Benjamin, EJ; Gona, P; Larson, MG; Levy, D; Lieb, W; Tofler, GH; Vasan, RS; Velagaleti, RS; Wang, TJ, 2008) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| " The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied." | 3.71 | Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 3.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| " Even though the angiotensin converting enzyme inhibitor captopril was previously found to attenuate this interstitial and perivascular fibrosis, the relative importance of arterial and ventricular systolic pressures versus circulating angiotensin II (AII) and aldosterone (AL) in promoting hypertrophy and collagen accumulation in renovascular hypertension is uncertain." | 3.68 | Remodeling of the rat right and left ventricles in experimental hypertension. ( Brilla, CG; Janicki, JS; Pick, R; Tan, LB; Weber, KT, 1990) |
| "To study the effects of a novel angiotensin I converting enzyme inhibitor (ACEI) on hypertension-induced cardiac hypertrophy, benazepril hydrochloride (CGS 14824 A, CAS 86541-74-4) at the dose of 3 and 10 mg/kg/d p." | 3.68 | Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. ( Hasegawa, Y; Inukai, T; Katahira, J; Nakao, K; Takemori, E, 1991) |
| "To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8." | 3.68 | Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990) |
| "The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment." | 3.68 | Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992) |
| "To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p." | 3.67 | [Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985) |
| "Primary aldosteronism is the most common cause of mineralocorticoid-induced hypertension, and MR antagonism offers the best prospect for achieving therapeutic goals." | 2.44 | Mineralocorticoid antagonism and cardiac hypertrophy. ( Nagata, K, 2008) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 2.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "Aldosterone has several deleterious properties." | 2.41 | Aldosterone: cardiovascular assault. ( Struthers, AD, 2002) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 2.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| "Cyclovirobuxine D (CVB-D) is a natural alkaloid that exhibits multiple pharmacological activities, such as anti-inflammatory, anti-oxidative stress, and anti-cancer properties." | 1.91 | Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3. ( An, J; Chen, Y; Fu, L; Liang, G; Shen, X; Tao, L; Wang, X; Wu, H; Zhang, G, 2023) |
| "Thus, BST-1 may exacerbate cardiac hypertrophy by activating the Ca2+/CaN/NFATc3 pathway." | 1.91 | BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway. ( Cao, H; Fu, L; Huang, F; Li, A; Li, S; Liao, C; Wang, X; Yuan, Y; Zeng, W; Zhang, B; Zhao, L, 2023) |
| "It showed that cardiac hypertrophy was associated with obesity while microalbuminuria was related to plasma aldosterone concentration (PAC) in PA patients." | 1.72 | Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. ( Bu, X; He, H; Li, Y; Liu, X; Sun, F; Yan, Z; Zhang, H; Zhao, Z; Zhu, Z, 2022) |
| "Primary aldosteronism is characterized by excess aldosterone secretion by the adrenal gland independent of the renin-angiotensin system and accounts for ~10% of hypertensive patients." | 1.48 | MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. ( Ball, JP; Hall, ME; Mathis, KW; Romero, DG; Rothenberg, ME; Ryan, MJ; Syed, M; Yanes Cardozo, LL, 2018) |
| "Furthermore, cardiac hypertrophy and sclerosis of the arteries of various organs had progressed, suggesting an influence of persistent endocrinal hypertension." | 1.39 | An autopsy case of bilateral adrenal pheochromocytoma-associated cerebral hemorrhage. ( Fukunaga, T; Hara, S; Kobayashi, M; Kuriiwa, F; Mizukami, H; Mori, S, 2013) |
| "Arterial hypertension (AH) induces cardiac hypertrophy and reactivation of "fetal" gene expression." | 1.38 | Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. ( Azibani, F; Carrier, L; Chatziantoniou, C; Coutance, G; Delcayre, C; Devaux, Y; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Solal, AC, 2012) |
| "To prevent cardiac hypertrophy and heart failure, it is necessary to identify and characterize molecules that may regulate the hypertrophic program." | 1.36 | miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. ( Li, PF; Long, B; Wang, K; Zhou, J, 2010) |
| "Despite displaying cardiac hypertrophy at baseline and higher blood pressure responses to L-NAME/AngII, cav-1 KO mice displayed, as compared with WT, decreased treatment-induced biventricular damage as well as decreased transcript levels of the proinflammatory marker plasminogen activator inhibitor-1." | 1.36 | Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. ( Adler, GK; Coutinho, P; Guo, C; Lapointe, N; Loutraris, P; Pojoga, LH; Ricchiuti, V; Romero, JR; Stone, JR; Williams, GH; Yao, TM, 2010) |
| "Aldosterone (ALDO) may induce cardiac hypertrophy by nonhemodynamic mechanisms that are not completely defined." | 1.35 | Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. ( Díez, J; Fortuño, MA; Gallego, I; Iñigo, C; López-Andrés, N, 2008) |
| "Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0." | 1.35 | Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009) |
| "Cardiac hypertrophy is accompanied by maladaptive cardiac remodeling, which leads to heart failure or sudden death." | 1.35 | miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. ( Gao, J; Jiao, J; Li, PF; Lin, Z; Murtaza, I; Wang, K, 2009) |
| "Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis." | 1.33 | Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006) |
| "However, tempol failed to suppress cardiac hypertrophy, the formation of inflammatory lesions, and upregulation of cardiac MCP-1 and osteopontin by aldosterone, while N-acetylcysteine could inhibit all of them." | 1.33 | Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. ( Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Ueda, M; Wake, R; Yoshida, K; Yoshiyama, M; Yukimura, T, 2005) |
| "The GK rats developed hypertension, cardiac hypertrophy and overexpression of cardiac natriuretic peptides and profibrotic connective tissue growth factor compared to nondiabetic Wistar rats." | 1.33 | Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. ( Bäcklund, T; Cheng, ZJ; Eriksson, A; Finckenberg, P; Grönholm, T; Laine, M; Mervaala, E; Palojoki, E; Tikkanen, I; Vuolteenaho, O, 2005) |
| " To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity." | 1.33 | Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. ( Arias-Loza, PA; Bauersachs, J; Ertl, G; Fritzemeier, KH; Galle, J; Hegele-Hartung, C; Hu, K; Jazbutyte, V; Neyses, L; Pelzer, T; Quaschning, T; Schäfer, A, 2006) |
| "Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure." | 1.32 | Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003) |
| "These results demonstrate that residual aldosterone has a significant impact on target-organ damage in hypertension, even during chronic administration of an ARB." | 1.32 | Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. ( Hara, Y; Imaki, T; Naruse, M; Nishikawa, T; Sato, A; Takano, K; Tanabe, A; Tsuchiya, K, 2004) |
| "1." | 1.32 | Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. ( De Smet, HR; Menadue, MF; Oliver, JR; Phillips, PA, 2003) |
| "Spironolactone prevented cardiac hypertrophy in adrenalectomized SHRSP." | 1.31 | Cardiac aldosterone production in genetically hypertensive rats. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000) |
| " Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan." | 1.31 | Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. ( Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002) |
| "High sodium intake causes cardiac hypertrophy independently of increases in blood pressure." | 1.31 | Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000) |
| "L-NAME treatment induced hypertension that was associated with increased plasma renin activity." | 1.30 | Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. ( Brosnan, MJ; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; McIntyre, M; McPhaden, AR; Morton, JJ; Reid, JL, 1998) |
| "A case of primary hyperaldosteronism and cardiomegaly due to a unilateral adrenal adenoma in a newborn is presented." | 1.30 | Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. ( Armanini, D; Cecchetto, G; Fassina, A; Opocher, G; Pozzan, GB; Rigon, F; Zacchello, F, 1997) |
| " Co-administration with propranolol markedly decreased the heart rate, but little affected the heart weight, suggesting changes in the heart rate during the long-term administration of KW-3049 did not largely affect cardiac hypertrophy." | 1.29 | Effect of the new calcium antagonist (+/-)-(R*)-3-[(R*)-1-benzyl-3- piperidyl] methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5- pyridinedicarboxylate hydrochloride (KW-3049) on cardiac hypertrophy in spontaneously hypertensive rats. ( Deguchi, T; Hara, T; Hattori, O; Kato, Y; Saijyo, T; Suzuki, K; Tanaka, H, 1993) |
| " Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)." | 1.28 | Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992) |
| "Hence, cardiac hypertrophy during chronic exposure to cold is supported by other factors, possibly by the increased concentration of either norepinephrine or triiodothyronine, or both, which occurs characteristically in rats under these conditions." | 1.28 | Effect of a reduction in sodium intake on cold-induced elevation of blood pressure in the rat. ( Fregly, MJ; Papanek, PE; van Bergen, P, 1992) |
| "Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension." | 1.28 | Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992) |
| " Thus, in the presence of enhanced sodium intake, chronic administration of ALDO or DOCA are associated with collagen accumulation in the myocardium, whereas with the mineralocorticoid-like compound GA, myocardial fibrosis was not seen." | 1.28 | Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. ( Brilla, CG; Weber, KT, 1992) |
| "Aldosterone excretion was in HL with EH substantially lower, and sodium excretion higher, than in a comparable group of lowland inhabitants." | 1.27 | Prevalence and clinical peculiarities of essential hypertension in a population living at high altitude. ( Dzhumagulova, AS; Meimanaliev, TS; Mirrakhimov, MM; Murataliev, TM; Rafibekova, ZhS; Shatemirova, KK, 1985) |
| "Patients with primary aldosteronism and unilateral renovascular hypertension of similar blood pressure levels, age and sex have almost identical degrees of left ventricular hypertrophy and anatomy." | 1.27 | Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. ( Abe, H; Ashizawa, A; Iwata, S; Kuramochi, M; Nagata, S; Omae, T; Saitoh, F; Suzuki, T, 1988) |
| "A case of an adult with Bartter's syndrome (hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis) is described; the patient had the unusual manifestation of cardiomyopathy, probably secondary to severe hypokalemia." | 1.26 | Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies. ( Dalakos, TG; Jones, D; Potts, JL; Streeten, DH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (13.67) | 18.7374 |
| 1990's | 28 (20.14) | 18.2507 |
| 2000's | 49 (35.25) | 29.6817 |
| 2010's | 38 (27.34) | 24.3611 |
| 2020's | 5 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, X | 1 |
| Sun, F | 1 |
| Zhang, H | 1 |
| Liu, X | 1 |
| Zhao, Z | 1 |
| He, H | 1 |
| Li, Y | 1 |
| Yan, Z | 1 |
| Zhu, Z | 1 |
| Yuan, Y | 1 |
| Zhao, L | 1 |
| Cao, H | 1 |
| Li, S | 4 |
| Liao, C | 1 |
| Fu, L | 2 |
| Wang, X | 3 |
| Huang, F | 1 |
| Zeng, W | 1 |
| Li, A | 1 |
| Zhang, B | 1 |
| Kmieć, P | 1 |
| Rosenkranz, S | 1 |
| Odenthal, M | 1 |
| Caglayan, E | 1 |
| Wu, H | 1 |
| An, J | 1 |
| Zhang, G | 1 |
| Chen, Y | 2 |
| Tao, L | 1 |
| Liang, G | 1 |
| Shen, X | 1 |
| Cao, W | 1 |
| Wang, B | 1 |
| Zhan, E | 1 |
| Xu, J | 2 |
| Slavic, S | 1 |
| Ford, K | 1 |
| Modert, M | 1 |
| Becirovic, A | 1 |
| Handschuh, S | 1 |
| Baierl, A | 1 |
| Katica, N | 1 |
| Zeitz, U | 1 |
| Erben, RG | 1 |
| Andrukhova, O | 1 |
| Chou, CH | 1 |
| Hung, CS | 1 |
| Liao, CW | 1 |
| Wei, LH | 1 |
| Chen, CW | 1 |
| Shun, CT | 1 |
| Wen, WF | 1 |
| Wan, CH | 1 |
| Wu, XM | 1 |
| Chang, YY | 1 |
| Wu, VC | 1 |
| Wu, KD | 1 |
| Lin, YH | 1 |
| de Paula Vasconcelos, PC | 1 |
| Tirloni, CAS | 1 |
| Palozi, RAC | 1 |
| Leitão, MM | 1 |
| Carneiro, MTS | 1 |
| Schaedler, MI | 1 |
| Silva, AO | 1 |
| Souza, RIC | 1 |
| Salvador, MJ | 1 |
| Junior, AG | 1 |
| Kassuya, CAL | 1 |
| Newhard, DK | 1 |
| Jung, S | 1 |
| Winter, RL | 1 |
| Duran, SH | 1 |
| Syed, M | 1 |
| Ball, JP | 1 |
| Mathis, KW | 1 |
| Hall, ME | 1 |
| Ryan, MJ | 1 |
| Rothenberg, ME | 1 |
| Yanes Cardozo, LL | 1 |
| Romero, DG | 1 |
| Araos, P | 1 |
| Prado, C | 1 |
| Lozano, M | 1 |
| Figueroa, S | 1 |
| Espinoza, A | 1 |
| Berger, T | 1 |
| Mak, TW | 1 |
| Jaisser, F | 1 |
| Pacheco, R | 1 |
| Michea, L | 1 |
| Amador, CA | 1 |
| Duda, T | 1 |
| Pertzev, A | 1 |
| Sharma, RK | 1 |
| Yasuoka, S | 1 |
| Kai, H | 1 |
| Kajimoto, H | 1 |
| Kudo, H | 1 |
| Takayama, N | 1 |
| Anegawa, T | 1 |
| Koga, M | 1 |
| Miyamoto, T | 1 |
| Mifune, H | 1 |
| Kage, M | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 1 |
| Masutani, S | 1 |
| Saiki, H | 1 |
| Kurishima, C | 1 |
| Ishido, H | 1 |
| Tamura, M | 1 |
| Senzaki, H | 1 |
| Gómez, AM | 1 |
| Ruiz-Hurtado, G | 1 |
| Benitah, JP | 1 |
| Domínguez-Rodríguez, A | 1 |
| Katayama, IA | 2 |
| Pereira, RC | 1 |
| Dopona, EP | 1 |
| Shimizu, MH | 1 |
| Furukawa, LN | 2 |
| Oliveira, IB | 2 |
| Heimann, JC | 2 |
| Martín-Fernández, B | 2 |
| Valero Muñoz, M | 1 |
| de las Heras, N | 2 |
| Ballesteros, S | 2 |
| Lahera, V | 2 |
| Park, BM | 1 |
| Gao, S | 1 |
| Cha, SA | 1 |
| Kim, SH | 1 |
| Bernhardt, R | 1 |
| Sakamuri, SS | 1 |
| Valente, AJ | 2 |
| Siddesha, JM | 1 |
| Delafontaine, P | 1 |
| Siebenlist, U | 2 |
| Gardner, JD | 1 |
| Bysani, C | 1 |
| Mummidi, S | 1 |
| Das, NA | 1 |
| Carpenter, AJ | 1 |
| Kandikattu, H | 1 |
| Krenz, M | 1 |
| Chandrasekar, B | 1 |
| Okoshi, MP | 1 |
| Cezar, MDM | 1 |
| Iyomasa, RM | 1 |
| Silva, MB | 1 |
| Costa, LCO | 1 |
| Martinez, PF | 1 |
| Campos, DHS | 1 |
| Damatto, RL | 1 |
| Minicucci, MF | 1 |
| Cicogna, AC | 1 |
| Okoshi, K | 1 |
| Furuzono, S | 1 |
| Meguro, M | 1 |
| Miyauchi, S | 1 |
| Inoue, S | 1 |
| Homma, T | 1 |
| Yamada, K | 1 |
| Tagawa, YI | 1 |
| Nara, F | 1 |
| Nagayama, T | 1 |
| López-Andrés, N | 1 |
| Iñigo, C | 1 |
| Gallego, I | 1 |
| Díez, J | 1 |
| Fortuño, MA | 1 |
| Nagata, K | 2 |
| Velagaleti, RS | 1 |
| Gona, P | 1 |
| Levy, D | 1 |
| Aragam, J | 1 |
| Larson, MG | 1 |
| Tofler, GH | 1 |
| Lieb, W | 1 |
| Wang, TJ | 1 |
| Benjamin, EJ | 1 |
| Vasan, RS | 1 |
| Aplin, M | 1 |
| Christensen, GL | 1 |
| Hansen, JL | 1 |
| Kawai, M | 1 |
| Hongo, K | 1 |
| Komukai, K | 1 |
| Morimoto, S | 1 |
| Nagai, M | 1 |
| Seki, S | 1 |
| Taniguchi, I | 2 |
| Mochizuki, S | 2 |
| Yoshimura, M | 2 |
| Klusonová, P | 1 |
| Reháková, L | 1 |
| Borchert, G | 1 |
| Vagnerová, K | 1 |
| Neckár, J | 1 |
| Ergang, P | 1 |
| Miksík, I | 1 |
| Kolár, F | 1 |
| Pácha, J | 1 |
| Park, JK | 1 |
| Theuer, S | 1 |
| Kirsch, T | 1 |
| Lindschau, C | 1 |
| Klinge, U | 1 |
| Heuser, A | 1 |
| Plehm, R | 1 |
| Todiras, M | 1 |
| Carmeliet, P | 1 |
| Haller, H | 1 |
| Luft, FC | 2 |
| Muller, DN | 2 |
| Fiebeler, A | 1 |
| Lin, Z | 1 |
| Murtaza, I | 1 |
| Wang, K | 2 |
| Jiao, J | 1 |
| Gao, J | 1 |
| Li, PF | 2 |
| Peters, J | 1 |
| Schlüter, T | 1 |
| Riegel, T | 1 |
| Peters, BS | 1 |
| Beineke, A | 1 |
| Maschke, U | 1 |
| Hosten, N | 1 |
| Mullins, JJ | 1 |
| Rettig, R | 1 |
| Bibeau, K | 1 |
| Battista, MC | 1 |
| Houde, V | 1 |
| Brochu, M | 1 |
| Pojoga, LH | 1 |
| Romero, JR | 1 |
| Yao, TM | 1 |
| Loutraris, P | 1 |
| Ricchiuti, V | 1 |
| Coutinho, P | 1 |
| Guo, C | 1 |
| Lapointe, N | 1 |
| Stone, JR | 1 |
| Adler, GK | 1 |
| Williams, GH | 1 |
| Long, B | 1 |
| Zhou, J | 2 |
| Shi, H | 1 |
| Ma, C | 1 |
| Liu, Y | 2 |
| Hu, Z | 1 |
| Wu, D | 1 |
| Wang, BH | 1 |
| Bertucci, MC | 1 |
| Ma, JY | 1 |
| Adrahtas, A | 1 |
| Cheung, RY | 1 |
| Krum, H | 1 |
| Martinez, FA | 1 |
| Wang, Q | 1 |
| Maillard, M | 1 |
| Schibler, U | 1 |
| Burnier, M | 1 |
| Gachon, F | 1 |
| Usher, MG | 1 |
| Duan, SZ | 1 |
| Ivaschenko, CY | 1 |
| Frieler, RA | 1 |
| Berger, S | 1 |
| Schütz, G | 1 |
| Lumeng, CN | 1 |
| Mortensen, RM | 1 |
| Ferreira, DN | 1 |
| Rosa, KT | 1 |
| Coelho, MS | 1 |
| Casarini, DE | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Ferron, L | 1 |
| Ruchon, Y | 1 |
| Renaud, JF | 1 |
| Capuano, V | 1 |
| Kurdi, M | 1 |
| Booz, GW | 1 |
| He, T | 1 |
| Chen, L | 1 |
| Han, Y | 1 |
| Yang, WQ | 1 |
| Jin, MW | 1 |
| Miana, M | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Davel, AP | 1 |
| Rossoni, LV | 1 |
| Cachofeiro, V | 1 |
| Yoneda, T | 5 |
| Demura, M | 4 |
| Takata, H | 2 |
| Kometani, M | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 2 |
| Takeda, Y | 6 |
| Komatsu, Y | 1 |
| Kida, N | 1 |
| Nozaki, N | 1 |
| Kuwasako, K | 1 |
| Nagata, S | 2 |
| Kitamura, K | 1 |
| Kato, J | 1 |
| Azibani, F | 2 |
| Devaux, Y | 1 |
| Coutance, G | 1 |
| Schlossarek, S | 1 |
| Polidano, E | 1 |
| Fazal, L | 2 |
| Merval, R | 1 |
| Carrier, L | 1 |
| Solal, AC | 1 |
| Chatziantoniou, C | 2 |
| Launay, JM | 1 |
| Samuel, JL | 2 |
| Delcayre, C | 3 |
| Birner, C | 1 |
| Ulucan, C | 1 |
| Bratfisch, M | 1 |
| Götz, T | 1 |
| Dietl, A | 1 |
| Schweda, F | 1 |
| Riegger, GA | 1 |
| Luchner, A | 1 |
| Mizukami, H | 1 |
| Hara, S | 1 |
| Kobayashi, M | 1 |
| Mori, S | 1 |
| Kuriiwa, F | 1 |
| Fukunaga, T | 1 |
| Mezősi, E | 1 |
| Bajnok, L | 1 |
| Tóth, K | 1 |
| Karram, T | 1 |
| Hoffman, A | 1 |
| Abbasi, A | 1 |
| Abassi, Z | 1 |
| Oshima, Y | 1 |
| Fujio, Y | 1 |
| Funamoto, M | 1 |
| Negoro, S | 1 |
| Izumi, M | 1 |
| Nakaoka, Y | 1 |
| Hirota, H | 1 |
| Yamauchi-Takihara, K | 1 |
| Kawase, I | 1 |
| Young, MJ | 3 |
| Funder, JW | 8 |
| Struthers, AD | 1 |
| De Smet, HR | 1 |
| Menadue, MF | 1 |
| Oliver, JR | 1 |
| Phillips, PA | 1 |
| Qin, W | 1 |
| Rudolph, AE | 1 |
| Bond, BR | 1 |
| Rocha, R | 1 |
| Blomme, EA | 1 |
| Goellner, JJ | 1 |
| McMahon, EG | 2 |
| Sheppard, KE | 2 |
| KLAUSGRABER, F | 1 |
| Karmazyn, M | 1 |
| Liu, Q | 1 |
| Gan, XT | 1 |
| Brix, BJ | 1 |
| Fliegel, L | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Bedigian, MP | 1 |
| Robinson, AD | 1 |
| Weber, KT | 5 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 2 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Matsui, Y | 1 |
| Jia, N | 1 |
| Okamoto, H | 1 |
| Kon, S | 1 |
| Onozuka, H | 1 |
| Akino, M | 1 |
| Liu, L | 1 |
| Morimoto, J | 1 |
| Rittling, SR | 1 |
| Denhardt, D | 1 |
| Kitabatake, A | 1 |
| Uede, T | 1 |
| Schlüter, KD | 1 |
| Wollert, KC | 1 |
| Neuberger, HR | 1 |
| Schotten, U | 1 |
| Verheule, S | 1 |
| Eijsbouts, S | 1 |
| Blaauw, Y | 1 |
| van Hunnik, A | 1 |
| Allessie, M | 1 |
| Grönholm, T | 1 |
| Cheng, ZJ | 1 |
| Palojoki, E | 1 |
| Eriksson, A | 1 |
| Bäcklund, T | 1 |
| Vuolteenaho, O | 1 |
| Finckenberg, P | 1 |
| Laine, M | 1 |
| Mervaala, E | 1 |
| Tikkanen, I | 1 |
| Yoshida, K | 1 |
| Kim-Mitsuyama, S | 1 |
| Wake, R | 1 |
| Izumiya, Y | 1 |
| Izumi, Y | 1 |
| Yukimura, T | 1 |
| Ueda, M | 1 |
| Yoshiyama, M | 1 |
| Iwao, H | 1 |
| Obata, K | 1 |
| Ichihara, S | 1 |
| Noda, A | 1 |
| Kimata, H | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Lister, K | 1 |
| Autelitano, DJ | 1 |
| Jenkins, A | 1 |
| Hannan, RD | 1 |
| Rodríguez-Ayala, E | 1 |
| Avila-Díaz, M | 1 |
| Foyo-Niembro, E | 1 |
| Amato, D | 1 |
| Ramirez-San-Juan, E | 1 |
| Paniagua, R | 1 |
| Chappell, MC | 1 |
| Yamaleyeva, LM | 1 |
| Westwood, BM | 1 |
| Odedra, K | 1 |
| Ferro, A | 1 |
| Franco, V | 1 |
| Chen, YF | 1 |
| Feng, JA | 1 |
| Li, P | 1 |
| Wang, D | 1 |
| Hasan, E | 1 |
| Oparil, S | 1 |
| Perry, GJ | 1 |
| Arias-Loza, PA | 1 |
| Hu, K | 1 |
| Schäfer, A | 1 |
| Bauersachs, J | 1 |
| Quaschning, T | 1 |
| Galle, J | 1 |
| Jazbutyte, V | 1 |
| Neyses, L | 1 |
| Ertl, G | 1 |
| Fritzemeier, KH | 1 |
| Hegele-Hartung, C | 1 |
| Pelzer, T | 1 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Abe, Y | 1 |
| Zhu, A | 1 |
| Usukura, M | 2 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Kagiyama, S | 1 |
| Matsumura, K | 1 |
| Fukuhara, M | 1 |
| Sakagami, K | 1 |
| Fujii, K | 1 |
| Iida, M | 1 |
| Klanke, B | 1 |
| Feldt, S | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 2 |
| Hilgers, KF | 1 |
| Sun, Z | 1 |
| Bello-Roufai, M | 1 |
| Hartford, M | 1 |
| Wikstrand, J | 1 |
| Wallentin, I | 1 |
| Ljungman, S | 1 |
| Berglund, G | 1 |
| Prys-Roberts, C | 1 |
| Raman, VK | 1 |
| Lee, YA | 1 |
| Lindpaintner, K | 1 |
| Kato, Y | 1 |
| Tanaka, H | 1 |
| Saijyo, T | 1 |
| Hattori, O | 1 |
| Suzuki, K | 1 |
| Hara, T | 1 |
| Deguchi, T | 1 |
| Modena, MG | 1 |
| Masciocco, G | 1 |
| Mattioli, G | 1 |
| Pouleur, H | 1 |
| Zannad, F | 1 |
| Pozzan, GB | 1 |
| Armanini, D | 1 |
| Cecchetto, G | 1 |
| Opocher, G | 1 |
| Rigon, F | 1 |
| Fassina, A | 1 |
| Zacchello, F | 1 |
| González Quijada, S | 1 |
| Luque Otero, M | 1 |
| Fernández-Cruz, A | 1 |
| Almería, C | 1 |
| Bagazgoitia Barrera, J | 1 |
| Moya Marín, FJ | 1 |
| Devlin, AM | 1 |
| Brosnan, MJ | 1 |
| Graham, D | 1 |
| Morton, JJ | 1 |
| McPhaden, AR | 1 |
| McIntyre, M | 1 |
| Hamilton, CA | 1 |
| Reid, JL | 1 |
| Dominiczak, AF | 1 |
| Silvestre, JS | 1 |
| Heymes, C | 1 |
| Oubénaïssa, A | 1 |
| Robert, V | 1 |
| Aupetit-Faisant, B | 1 |
| Carayon, A | 1 |
| Swynghedauw, B | 1 |
| Miyamori, I | 2 |
| Mabuchi, H | 3 |
| Farina, NK | 1 |
| Johnston, CI | 1 |
| Burrell, LM | 1 |
| Remme, WJ | 1 |
| Shimamura, T | 1 |
| Iwasaki, T | 1 |
| Hayasaki-Kajiwara, Y | 1 |
| Naya, N | 1 |
| Nakajima, M | 1 |
| Xiu, JC | 1 |
| Wu, P | 1 |
| Xu, JP | 1 |
| Guo, Z | 1 |
| Lai, W | 1 |
| Zhang, Y | 1 |
| Li, J | 1 |
| Potts, JL | 1 |
| Dalakos, TG | 1 |
| Streeten, DH | 1 |
| Jones, D | 1 |
| Wilkins, GE | 1 |
| Scavo, D | 1 |
| Cugini, P | 1 |
| Manconi, R | 1 |
| Serdoz, R | 1 |
| Takeda, K | 1 |
| Nakata, T | 1 |
| Kuwabara, T | 1 |
| Itoh, H | 1 |
| Yamahara, Y | 1 |
| Takesako, T | 1 |
| Tanabe, S | 1 |
| Sasaki, S | 1 |
| Asayama, J | 1 |
| Nakagawa, M | 1 |
| Agabiti-Rosei, E | 2 |
| Muiesan, ML | 2 |
| Rizzoni, D | 1 |
| Zulli, R | 1 |
| Calebich, S | 1 |
| Beschi, M | 2 |
| Castellano, M | 2 |
| Muiesan, G | 2 |
| van Bergen, P | 1 |
| Fregly, MJ | 1 |
| Papanek, PE | 1 |
| Resnick, LM | 1 |
| Brilla, CG | 4 |
| Dittrich, HC | 1 |
| Adler, J | 1 |
| Ong, J | 1 |
| Reitman, M | 1 |
| Weber, M | 1 |
| Ziegler, M | 1 |
| Pick, R | 1 |
| Tan, LB | 1 |
| Janicki, JS | 1 |
| Bauwens, FR | 1 |
| Duprez, DA | 1 |
| De Buyzere, ML | 1 |
| De Backer, TL | 1 |
| Kaufman, JM | 2 |
| Van Hoecke, J | 2 |
| Vermeulen, A | 2 |
| Clement, DL | 2 |
| Takemori, E | 1 |
| Hasegawa, Y | 1 |
| Katahira, J | 1 |
| Nakao, K | 1 |
| Inukai, T | 1 |
| De la Sierra, A | 1 |
| Coca, A | 1 |
| Sobrino, J | 1 |
| Lluch, MM | 1 |
| Sánchez, M | 1 |
| Urbano-Márquez, A | 1 |
| Duprez, D | 1 |
| Bauwens, F | 1 |
| De Buyzere, M | 1 |
| De Backer, T | 1 |
| Julien, J | 1 |
| Dufloux, MA | 1 |
| Prasquier, R | 1 |
| Chatellier, G | 1 |
| Menard, D | 1 |
| Plouin, PF | 1 |
| Menard, J | 1 |
| Corvol, P | 1 |
| Allard, MF | 1 |
| DeVenny, MF | 1 |
| Doss, LK | 1 |
| Grizzle, WE | 1 |
| Bishop, SP | 1 |
| Fernandez, D | 1 |
| Bolli, P | 1 |
| Snedden, W | 1 |
| Vasdev, S | 1 |
| Fernandez, PG | 1 |
| Narita, H | 1 |
| Nagao, T | 1 |
| Inamasu, M | 1 |
| Iwasaki, HO | 1 |
| Morita, T | 1 |
| Martin, AF | 1 |
| Paul, RJ | 1 |
| Suzuki, T | 1 |
| Abe, H | 1 |
| Saitoh, F | 1 |
| Iwata, S | 1 |
| Ashizawa, A | 1 |
| Kuramochi, M | 1 |
| Omae, T | 1 |
| Messerli, FH | 1 |
| Garavaglia, GE | 1 |
| Nunez, B | 1 |
| MacPhee, AA | 1 |
| Re, RN | 1 |
| Pringle, SD | 1 |
| Macfarlane, PW | 1 |
| Isles, CG | 1 |
| Cameron, HL | 1 |
| Brown, IA | 1 |
| Lorimer, AR | 1 |
| Dunn, FG | 1 |
| Geri, A | 1 |
| Romanelli, G | 1 |
| Andersson, U | 1 |
| Sylvén, C | 1 |
| Lindvall, K | 1 |
| Theodorsson, E | 1 |
| Norée, LO | 1 |
| Mirrakhimov, MM | 1 |
| Rafibekova, ZhS | 1 |
| Dzhumagulova, AS | 1 |
| Meimanaliev, TS | 1 |
| Murataliev, TM | 1 |
| Shatemirova, KK | 1 |
| Trimarco, B | 1 |
| Ricciardelli, B | 1 |
| De Luca, N | 1 |
| De Simone, A | 1 |
| Cuocolo, A | 1 |
| Galva, MD | 1 |
| Picotti, GB | 1 |
| Condorelli, M | 1 |
| Christenson, WB | 1 |
| Kaufman, JJ | 1 |
| Gonick, HC | 1 |
| Brunner, HR | 1 |
| Laragh, JH | 1 |
| Baer, L | 1 |
| Newton, MA | 1 |
| Goodwin, FT | 1 |
| Krakoff, LR | 1 |
| Bard, RH | 1 |
| Bühler, FR | 1 |
| Serebrovskaia, IuA | 1 |
| Kiseleva, ZM | 1 |
| Speranskaia, NV | 1 |
| Spivak, GL | 1 |
| Paleeva, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Salt Sensitive Hypertension and Striatin[NCT03683069] | Phase 4 | 400 participants (Actual) | Interventional | 2019-01-15 | Active, not recruiting | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| Addressing HyperteNsion and Diabetes Through Community-Engaged Systems in Puno, Peru (ANDES Study)[NCT05524987] | 1,068 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for aldosterone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy.
Topics: Aldosterone; Animals; Calcineurin; Calcium; Calcium Channels, L-Type; Calcium-Calmodulin-Dependent P | 2013 |
Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart.
Topics: Aldosterone; Animals; Cardiomegaly; Connective Tissue Growth Factor; Endothelium, Vascular; Fibrosis | 2014 |
The potential of targeting CYP11B.
Topics: Aldosterone; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Drug Design; Humans; Hypertension; Imi | 2016 |
Mineralocorticoid antagonism and cardiac hypertrophy.
Topics: Aldosterone; Antihypertensive Agents; Cardiomegaly; Fibrosis; Humans; Hyperaldosteronism; Hypertensi | 2008 |
Pharmacologic perspectives of functional selectivity by the angiotensin II type 1 receptor.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cardiomegaly; Cardiovascular D | 2008 |
[The heart as an endocrine organ].
Topics: Adipocytes; Adipokines; Aldosterone; Biomarkers; Cardiomegaly; Coronary Artery Disease; Cytokines; H | 2012 |
[Aldosterone--classic and non classic effects].
Topics: Aldosterone; Cardiomegaly; Collagen; Genes, ras; Heart; Humans; Muscle, Skeletal; Sodium Channels | 2002 |
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism | 2002 |
Aldosterone: cardiovascular assault.
Topics: Aldosterone; Autonomic Nervous System Diseases; Cardiomegaly; Endothelium, Vascular; Fibrinolysis; F | 2002 |
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr | 2002 |
Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aldosterone; Animals; Binding Sites; | 2003 |
Neurohormones and heart failure: the importance of aldosterone.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Aldosterone].
Topics: Aldosterone; Cardiomegaly; Heart Failure; Humans; Myocardium | 2007 |
Pathophysiology of hypertension and ischemic heart disease.
Topics: Adult; Aldosterone; Animals; Cardiomegaly; Coronary Circulation; Coronary Disease; Endocardium; Hear | 1980 |
The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; An | 1995 |
Role of neurohormones in ventricular adaptation and failure.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Animals; Cardiomegaly; Disease Models, Anima | 1994 |
Aldosterone and heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Endomyocardial Fibrosi | 1995 |
Mineralocorticoids, salt, hypertension: effects on the heart.
Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Heart; Humans; Hypertension; Hypokalemia; Mineralocort | 1996 |
Aldosterone action: fact, failure and the future.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Forecasti | 1998 |
Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders.
Topics: Aldosterone; Blood Glucose; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Diabete | 1992 |
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Models, Cardiovascular; Myocardi | 1991 |
5 trials available for aldosterone and Cardiac Hypertrophy
| Article | Year |
|---|---|
A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pr | 2018 |
Heart failure with preserved ejection fraction in children: hormonal imbalance between aldosterone and brain natriuretic peptide.
Topics: Adolescent; Adult; Age Factors; Aldosterone; Cardiomegaly; Child; Child, Preschool; Disease-Free Sur | 2013 |
The relation between cardiac hypertrophy and hypertension.
Topics: Aldosterone; Blood Glucose; Blood Pressure; Cardiomegaly; Heart Ventricles; Humans; Hypertension; In | 1983 |
Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension.
Topics: Aldosterone; Blood Pressure; Cardiomegaly; Delayed-Action Preparations; Double-Blind Method; Echocar | 1992 |
Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison.
Topics: Adult; Aged; Aldosterone; Captopril; Cardiomegaly; Double-Blind Method; Echocardiography; Humans; Hy | 1990 |
113 other studies available for aldosterone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome.
Topics: Albuminuria; Aldosterone; Cardiomegaly; Carotid Intima-Media Thickness; Glucose; Humans; Hyperaldost | 2022 |
BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway.
Topics: ADP-ribosyl Cyclase 1; Aldosterone; Animals; Calcium; Cardiomegaly; Cyclic ADP-Ribose; NFATC Transcr | 2023 |
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling.
Topics: Aldosterone; Animals; Cardiomegaly; Eplerenone; Fibrosis; Male; Mice; Mice, Transgenic; Myocytes, Ca | 2023 |
Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3.
Topics: Aldosterone; Cardiomegaly; Humans; Mitochondria; Molecular Docking Simulation; NF-E2-Related Factor | 2023 |
TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling.
Topics: Adaptor Proteins, Vesicular Transport; Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Fibrosi | 2020 |
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc | 2017 |
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.
Topics: Adult; Aldosterone; Animals; Cardiomegaly; Case-Control Studies; Cells, Cultured; Collagen; Cytokine | 2018 |
Diuretic herb Gomphrena celosioides Mart. (Amaranthaceae) promotes sustained arterial pressure reduction and protection from cardiac remodeling on rats with renovascular hypertension.
Topics: Aldosterone; Amaranthaceae; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Diuretic | 2018 |
MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Hyperaldosteronism; Male; Mice; Mice, Knockout; | 2018 |
Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; CD11 Antigens; Coculture Techniques; Dend | 2019 |
The ANF-RGC gene motif (669)WTAPELL(675) is vital for blood pressure regulation: biochemical mechanism.
Topics: Aldosterone; Amino Acid Motifs; Animals; Blood Pressure; Calcium; Cardiomegaly; Catalytic Domain; Ch | 2013 |
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Ep | 2013 |
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body | 2014 |
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cyclo | 2015 |
TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Adhes | 2016 |
Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; AMP-Activated Protein Kinases; Animals; Cardiomeg | 2016 |
Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload.
Topics: Aldosterone; Animals; Aortic Valve Stenosis; Cardiomegaly; Electrocardiography; Male; Mineralocortic | 2016 |
A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.
Topics: Aldosterone; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme Inhibitors; He | 2017 |
Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes.
Topics: Age Factors; Aldosterone; Animals; Cardiomegaly; Cell Line; Cytokines; Dose-Response Relationship, D | 2008 |
Relations of biomarkers representing distinct biological pathways to left ventricular geometry.
Topics: Aldosterone; Biomarkers; C-Reactive Protein; Cardiomegaly; Electrocardiography; Female; Fibrin; Hear | 2008 |
Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Vess | 2009 |
Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosteron | 2009 |
Growth arrest specific protein 6 participates in DOCA-induced target-organ damage.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Analysis of Variance; Animals; Blood Pressure; Cardio | 2009 |
miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy.
Topics: Aldosterone; Animals; Base Sequence; Calcineurin; Cardiomegaly; Cell Line; Disease Models, Animal; G | 2009 |
Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.
Topics: Administration, Oral; Aldosterone; Animals; Cardiomegaly; Collagen Type I; Cytochrome P-450 CYP1A1; | 2009 |
Fetal adrenal gland alterations in a rat model of adverse intrauterine environment.
Topics: Adrenal Glands; Aldosterone; Animals; Cardiomegaly; Corticosterone; Disease Models, Animal; DNA Prim | 2010 |
Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II.
Topics: Aldosterone; Amino Acid Sequence; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Caveolin 1; | 2010 |
miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.
Topics: Aldosterone; Animals; Base Sequence; Cardiomegaly; Gene Expression; Humans; In Vitro Techniques; Iso | 2010 |
[Inhibitory effect on activated renin-angiotensin system by astragaloside IV in rats with pressure-overload induced cardiac hypertrophy].
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Enzyme-Linked Immunosorbent Assa | 2009 |
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Car | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Cardiac hypertrophy, low blood pressure, and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Atenolol; Basic-Leucine Zipper Transcription Fact | 2010 |
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Fibrosis; Heart; Hypert | 2010 |
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
T-type Ca²+ signalling regulates aldosterone-induced CREB activation and cell death through PP2A activation in neonatal cardiomyocytes.
Topics: Aldosterone; Animals; Animals, Newborn; Apoptosis; bcl-X Protein; Calcium Channels, T-Type; Calcium | 2011 |
New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Inflammation; Mi | 2011 |
In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Collagen; D | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Topics: Adrenal Gland Neoplasms; Adult; Aldosterone; Antihypertensive Agents; Cardiomegaly; Enalapril; Human | 2012 |
Effects of proangiotensin-12 infused continuously over 14 days in conscious rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2012 |
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice.
Topics: Aldosterone; Animals; Cardiomegaly; Cyclic AMP Response Element-Binding Protein; Female; Fetus; Gene | 2012 |
[Hypertension-induced fibrosis: a balance story].
Topics: Aldosterone; Angiotensin II; Animals; Bone Morphogenetic Proteins; Cardiomegaly; Disease Models, Ani | 2012 |
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents; | 2012 |
An autopsy case of bilateral adrenal pheochromocytoma-associated cerebral hemorrhage.
Topics: Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Adult; Aldosterone; Arteries; Arteriosclerosis | 2013 |
Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway.
Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Endothelin-1; Enzyme Activati | 2002 |
Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats.
Topics: Aldosterone; Angiotensin II; Animals; Arginine Vasopressin; Blood Pressure; Cardiomegaly; Endothelin | 2003 |
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis | 2003 |
[Adrenal cortex hormone (Cortigarant) in heart therapy].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Cardiomegaly; Diuretics | 1962 |
Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes.
Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cell Size; Cells, Cultured; Enzyme Inhibitors; | 2003 |
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Th | 2004 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone | 2004 |
Vascular synthesis of aldosterone: role in hypertension.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Vessels; Cardi | 2004 |
Synchronization and integration of multiple hypertrophic pathways in the heart.
Topics: Aldosterone; Cardiomegaly; Cytokines; Humans; Integrins; Myocardium; Myocytes, Cardiac; Renin-Angiot | 2004 |
Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Atrial Natriuretic Factor; Cardiac Pacing | 2005 |
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Glu | 2005 |
Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress.
Topics: Acetylcysteine; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Chemokine CCL2; Echocardiography | 2005 |
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corti | 2006 |
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Corticosterone; Epleren | 2006 |
Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenal Cortex Hormones; Adrenergic Agents; Aldosterone | 2006 |
Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone.
Topics: Aldosterone; Animals; Apoptosis; Cardiomegaly; Fibrosis; Heart; Hypoparathyroidism; Male; Myocardium | 2006 |
Estrogen and salt sensitivity in the female mRen(2). Lewis rat.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Estrogens; Female; Gene Expressi | 2006 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy | 2006 |
Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats.
Topics: Aldosterone; Androstenes; Animals; Cardiomegaly; Cardiovascular System; Collagen; Estradiol; Estroge | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Ca | 2007 |
(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Hypertension, Renovascul | 2008 |
RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Cold Temperature; Dependovirus; Dis | 2008 |
Effect of the new calcium antagonist (+/-)-(R*)-3-[(R*)-1-benzyl-3- piperidyl] methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5- pyridinedicarboxylate hydrochloride (KW-3049) on cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegal | 1993 |
[Possible influence of hemodynamic and neurohormonal factors on the heart's response to arterial hypertension].
Topics: Adult; Aldosterone; Cardiomegaly; Female; Heart; Hemodynamics; Humans; Hypertension; Linear Models; | 1994 |
High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes.
Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cell Division; Cells, Cultured; Extracellular | 1996 |
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr | 1996 |
Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn.
Topics: Adenoma; Adrenalectomy; Aldosterone; Cardiomegaly; Humans; Hyperaldosteronism; Hypertension; Infant; | 1997 |
[Association between blood pressure and circulating hormonal factors with left ventricular mass in patients with essential hypertension older than 55 years of age].
Topics: Aged; Aldosterone; Cardiomegaly; Endothelin-1; Epinephrine; Female; Humans; Hypertension; Male; Midd | 1997 |
Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo.
Topics: Actins; Aldosterone; Animals; Aorta, Thoracic; Carbachol; Cardiomegaly; Cell Cycle; DNA; Heart; Hype | 1998 |
Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; C | 1999 |
Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Heart; Male; Myocardiu | 2000 |
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomeg | 2000 |
Cardiac aldosterone production in genetically hypertensive rats.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardi | 2000 |
Aldosterone and myocardial infarction--are aldosterone antagonists needed to prevent remodelling or does ACE inhibition suffice?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenoic Acid; Captopril; Cardiomegaly; Huma | 2001 |
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo | 2002 |
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
Topics: Aldosterone; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiomegaly; Circadian | 2002 |
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; | 2002 |
Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies.
Topics: Adult; Aldosterone; Bartter Syndrome; Cardiomegaly; Cardiomyopathies; Child; Female; Hemodynamics; H | 1977 |
Hypertension, hypokalemia, hyporeninemia and severe target organ damage.
Topics: Aldosterone; Blood Pressure; Cardiomegaly; Female; Humans; Hyperaldosteronism; Hypertension; Hypokal | 1976 |
[Comparative study of plasma levels of renin and aldosterone activity in essential arterial hypertension in relation to duration of the disease and the presence of complications].
Topics: Acute Disease; Adolescent; Adult; Aldosterone; Cardiomegaly; Chronic Disease; Female; Humans; Hypert | 1977 |
Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Coronary Circulation; C | 1992 |
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg | 1992 |
Effect of a reduction in sodium intake on cold-induced elevation of blood pressure in the rat.
Topics: Acclimatization; Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Cold Temperature; | 1992 |
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype | 1992 |
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Collagen; Desoxycorticosterone; Endomyocardial F | 1992 |
Remodeling of the rat right and left ventricles in experimental hypertension.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Fibrosis; Heart Ventricles; Hemodynami | 1990 |
Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Blood Pressure Determination; Cardiomegaly; Epinephrine; Female; | 1991 |
Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biomarkers; Blood Pres | 1991 |
Therapeutic response may be predicted by some clinical parameters in essential hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomegaly; | 1991 |
Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension.
Topics: Aldosterone; Blood Pressure; Cardiomegaly; Epinephrine; Female; Humans; Hypertension; Male; Middle A | 1991 |
Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Body Water; Cardiomegaly; Diet, Sodium-Restricted; Isoproterenol; Male; Organ | 1990 |
Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme.
Topics: Aldosterone; Animals; Body Weight; Cardiomegaly; Enalapril; Hypertension; Lisinopril; Peptidyl-Dipep | 1988 |
[Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR].
Topics: Aldosterone; Animals; Aorta; Aortic Diseases; Benzazepines; Cardiomegaly; Diltiazem; Hindlimb; Hyper | 1985 |
Isomyosin transitions in ventricles of aldosterone-salt hypertensive rats.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Electrophoresis, Polyacrylamide Gel | 1986 |
Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism.
Topics: Adult; Aldosterone; Blood Pressure; Blood Volume; Cardiomegaly; Echocardiography; Female; Humans; Hy | 1988 |
Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?
Topics: Aldosterone; Cardiomegaly; Female; Humans; Hypertension; Male; Myocardium; Renin-Angiotensin System; | 1988 |
Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism.
Topics: Adult; Aldosterone; Blood Pressure; Cardiomegaly; Electrocardiography; Humans; Hyperaldosteronism; M | 1988 |
Long-term antihypertensive treatment may induce normalization of left ventricular mass before complete regression of vascular structural changes: consequences for cardiac function at rest and during stress.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Catecholamines; Drug Admi | 1988 |
Cardiac function and cardiovascular hormone balance during hemodialysis with special reference to atrial natriuretic peptide.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Cardiomegaly; Echocardiography; Female; Heart; | 1988 |
Prevalence and clinical peculiarities of essential hypertension in a population living at high altitude.
Topics: Adult; Age Factors; Aldosterone; Alkalosis, Respiratory; Altitude; Altitude Sickness; Cardiomegaly; | 1985 |
Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents.
Topics: Adolescent; Adult; Aldosterone; Atenolol; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; C | 1985 |
Co-existing aldosterone-producing adrenal tumor (aldosteronoma) and bilateral renovascular lesions.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Angiography; Blood Pressure; Carbon Di | 1969 |
Essential hypertension: renin and aldosterone, heart attack and stroke.
Topics: Adult; Aldosterone; Cardiomegaly; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Mid | 1972 |
[Renin activity in the blood plasma in pheochromocytoma].
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aldosterone; Cardiomegaly; Catecholamines; Chromatograph | 1973 |